Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Jun Ueda, Hiroshi Funakoshi
Epigenome editing is fast becoming a promising technology for use in not only basic research but also various medical fields. Its applications are being studied for treatment of various diseases, including cancer, genetic diseases, and infectious diseases. Viral infections are known to cause epigenetic modifications in the host. Therefore, epigenome editing is a promising therapeutic approach which also has the capability to downregulate receptors for pathogen to enter the host. However, addressing the challenges of drug delivery systems is an essential and critical component for the success of these approaches. In this review, we briefly introduce the distinctive differences between genome editing and epigenome editing, highlight the challenges in application of the epigenome-editing approach to infectious diseases, and briefly outline the recent advances and challenges in drug delivery systems that are essential for therapeutic applications of epigenome editing. While further advances in delivery systems are needed, epigenome editing could be a potentially new generation of treatments and open new avenues for treating infectious diseases, in addition to genetic and other diseases.